Orthocell Limited
(ASX:OCC) has announced positive results from the pilot clinical study of its product, CelGro.
CelGro is a collagen-based medical device which assists with human tissue repair – for example, full thickness tendon tears in the shoulder.
Orthocell says that there are over 370,000 rotator cuff surgeries in the US every year, and large rotator cuff repairs regularly tear again, at a rate of up to 57 percent.
The company says that CelGro has been tested on three patients and, 42 days post operation, there have been no complications so far.
Orthocell reported a net loss of $2.35 million at 31 December 2015.
